Martin Orlowsky

The Fredonia College Foundation is a non-profit organization that supports the State University of New York at Fredonia by providing financial assistance to students, faculty, and staff. The foundation is based in Fredonia, NY. The foundation offers scholarships, grants, and other forms of aid to help students achieve their academic goals. It also supports research and other initiatives that enhance the educational experience at the university.

Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA.

Part of HealthCare Ventures LLC, Healthcare Strategic Partners, LLC is an American company that provides healthcare services.

Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA.

Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France.

Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen.

Futures Without Violence promotes and supports causes for human rights, health services, and the environment. It works for domestic violence prevention, education, advocacy, and public policy. The firm has worked to end violence against women and children around the world. The company is headquartered in San Francisco, CA.

New Balance Athletics, Inc. engages in the manufacturing and retailing of shoes. Its brands include New Balance, Dunham, PF Flyers, Aravon, Warrior and Brine. The firm offers lifestyle footwear for men and women, running accessories, sport and active casual bags, shoelaces, recovery gear products, sports monitors, technology socks, work boots, rugged casual footwear for men, sun wear and optical frames. The company was founded by William J. Riley in 1906 and is headquartered in Boston, MA.

Steven D. Bell & Co. provides commercial property brokerage and management services. It offers sales and finance services including transaction structuring and development. The company focuses on the acquisition, financing, ownership, management and disposition of quality apartment communities, shopping centers and senior housing properties in the Southeastern United States. The company was founded in 1976 by Steven D. Bell and is headquartered in Greensboro, NC.

Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA.

Part of Procter & Gamble Co., SmithKline & French SpA is a pharmaceutical concern. SmithKline & French was acquired by Procter & Gamble Co. from Smithkline Beecham Plc on September 29, 1993.

North Carolina Biosciences Organization is non-profit organization, which focuses on legislative monitoring and lobbying activities at the state and federal level. The company was founded in 1994 and is headquartered in Durham, NC.

HealthCare Ventures LLC (HealthCare Ventures) is a venture capital firm founded in 1985 by Harold R. Werner. The firm is headquartered in Cambridge, Massachusetts.

FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA.

LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA.

Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA.

Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Visionary Therapeutics Corp. develops ocular therapeutics for eye diseases. The company was founded by Steve Hutcherson and is headquartered in Richmond, VA